Efficacy and safety of spore-forming probiotics in functional dyspepsia: a randomised placebo-controlled trial

First-line therapy with proton pump inhibitors (PPI) has limited efficacy in functional dyspepsia (FD). Long term PPI treatment may cause intestinal dysbiosis. Altered duodenal luminal factors like the intestinal microbiota have been reported in FD patients. We studied spore-forming probiotics (combination of Bacillus coagulans MY01 and Bacillus subtilis MY02) as monotherapy or add-on to PPI in FD.